Biomatter raises $18M for new custom enzyme facility
In Lithuania, AI-powered custom enzyme designer Biomatter has closed an oversubscribed $18 million Series A round led by Astanor. Existing investors UVC Partners, Inventure and Metaplanet also participated. The funding will pay for a new 21,500 sq ft design-and-testing facility in Vilnius, opening in 2027.
“Our goal is to make a custom enzyme as easy to order as a catalog product, including for reactions that don’t have one today,” said Laurynas Karpus, CEO and co-founder of Biomatter.
The funds will also expand the commercial team and the company’s US presence, where roughly half its customers are based, and support its computational platform and enzyme dataset.
“Enzymes power hundreds of billions of dollars in food production and biomanufacturing. But because improving them takes months or years of trial and error, companies settle for suboptimal enzymes,” said Harry Briggs, Partner, Astanor. “Biomatter has spent years generating data beyond nature, which allows them to design enzymes that never evolved.”
Biomatter has delivered more than 50 custom enzymes to more than 25 enterprise customers in Europe, the United States and Japan, including AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos. It works across biopharma, diagnostics, agriculture and industrial biotech.
Category: Chemicals & Materials









